TABLE 1.
Clinical characteristics and measurements of lipids/lipoproteins
| Subjects with T2DM |
Nondiabetic Subjects |
||||
|---|---|---|---|---|---|
| Clinical | All Subjects | Females | Males | Females | Males |
| Number | N = 967 | N = 614 | N = 177 | N = 127 | N = 49 |
| Age (years) (mean ± SD) | 52.7 ± 15.5 | 55.0 ± 14.2 | 55.0 ± 15.0 | 45.0 ± 16.1 | 36.2 ± 15.6 |
| BMI (kg/m2) (mean ± SD) | 33.5 ± 7.9 | 34.3 ± 7.9 | 31.3 ± 6.53 | 34.1 ± 8.7 | 29.3 ± 7.4 |
| HbA1c (%) (mean ± SD) | 8.87 ± 2.22 | 8.94 ± 2.13 | 8.85 ± 2.41 | 5.79 ± 0.97 | NA |
| % Taking lipid-lowering medications | 11.89% | 14.73% | 10.98% | 2.84% | 0.57% |
| Conventional Lipid Panel | |||||
| Total cholesterol (mg/dl) (mean ± SD) | 196.7 ± 44. | 200.8 ± 44.8 | 190.9 ± 44.8 | 191.0 ± 43.4 | 183.0 ± 42.0 |
| TG (mg/dl) (mean ± SD) | 124.2 ± 85.1 | 128.0 ± 78.8 | 139.7 ± 110.8 | 91.6 ± 63.3 | 107.6 ± 83.4 |
| HDL cholesterol (mg/dl) (mean ± SD) | 49.0 ± 14.0 | 50.2 ± 13.6 | 43.2 ± 13.2 | 52.6 ± 15.0 | 46.2 ± 13.3 |
| Calculated LDL cholesterol (mg/dl) (mean ± SD) | 124.2 ± 40.0 | 126.1 ± 40.8 | 123.1 ± 39.7 | 119.3 ± 37.7 | 117.1 ± 36.8 |
| VLDL (mean ± SD) | 23.1 ± 12.5 | 24.2 ± 12.6 | 24.5 ± 12.3 | 17.4 ± 10.6 | 19.5 ± 11.6 |
| NMR Lipoprotein Subclass Analysis | |||||
| Large VLDL particle concentration (mg/dl) (mean ± SD | 22.6 ± 38.9 | 22.0 ± 36.8 | 33.9 ± 54.2 | 11.1 ± 17.6 | 14.3 ± 23.5 |
| VLDL mean particle size (nm) (mean ± SD) | 45.7 ± 7.4 | 45.8 ± 7.3 | 47.0 ± 8.6 | 43.2 ± 5.5 | 46.1 ± 8.4 |
| Small LDL particle concentration (mg/dl) (mean ± SD) | 20.1 ± 29.4 | 18.3 ± 28.3 | 31.7 ± 36.1 | 15.3 ± 23.4 | 10.8 ± 13.6 |
| LDL mean particle size (nm) (mean ± SD) | 21.0 ± 0.6 | 21.0 ± 0.6 | 20.7 ± 0.7 | 21.2 ± 0.6 | 21.1 ± 0.4 |
| Large HDL particle concentration (mg/dl) (mean ± SD) | 23.7 ± 11.5 | 25.0 ± 11.5 | 18.0 ± 10.04 | 25.8 ± 12.0 | 19.5 ± 7.0 |
| HDL mean particle size (nm) (mean ± SD) | 9.0 ± 0.4 | 9.0 ± 0.4 | 8.8 ± 0.4 | 9.1 ± 0.4 | 9.0 ± 0.4 |